These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 33799284)

  • 1. COVID-19 and the Risk of Relapse in Multiple Sclerosis Patients: A Fight with No Bystander Effect?
    Etemadifar M; Sedaghat N; Aghababaee A; Kargaran PK; Maracy MR; Ganjalikhani-Hakemi M; Rayani M; Abhari AP; Khorvash R; Salari M; Nouri H
    Mult Scler Relat Disord; 2021 Jun; 51():102915. PubMed ID: 33799284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Can coronavirus disease 2019 (COVID-19) trigger exacerbation of multiple sclerosis? A retrospective study.
    Barzegar M; Vaheb S; Mirmosayyeb O; Afshari-Safavi A; Nehzat N; Shaygannejad V
    Mult Scler Relat Disord; 2021 Jul; 52():102947. PubMed ID: 33979771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between relapses, stress, and depression in people with multiple sclerosis during the COVID-19 pandemic.
    Sparaco M; Miele G; Lavorgna L; Abbadessa G; Bonavita S
    Neurol Sci; 2022 May; 43(5):2935-2942. PubMed ID: 35092543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relapses after SARS-CoV-2 vaccination in patients with neuromyelitis optica spectrum disorder and multiple sclerosis.
    Kong L; Wang X; Chen H; Shi Z; Lang Y; Zhang Y; Zhou H
    Mult Scler Relat Disord; 2022 Dec; 68():104167. PubMed ID: 36170773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SARS-CoV-2 triggered relapse of multiple sclerosis.
    Finsterer J
    Clin Neurol Neurosurg; 2022 Apr; 215():107210. PubMed ID: 35305393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SARS-CoV-2 pandemic as a model to assess the relationship between intercurrent viral infections and disease activity in Multiple Sclerosis: A propensity score matched case-control study.
    Vercellino M; Bosa C; Alteno A; Muccio F; Marasciulo S; Garelli P; Cavalla P
    Mult Scler Relat Disord; 2023 Jun; 74():104715. PubMed ID: 37058763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does COVID-19 increase the long-term relapsing-remitting multiple sclerosis clinical activity? A cohort study.
    Etemadifar M; Abhari AP; Nouri H; Salari M; Maleki S; Amin A; Sedaghat N
    BMC Neurol; 2022 Feb; 22(1):64. PubMed ID: 35193507
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Personalizing ocrelizumab treatment in Multiple Sclerosis: What can we learn from Sars-Cov2 pandemic?
    Tazza F; Lapucci C; Cellerino M; Boffa G; Novi G; Poire I; Mancuso E; Bruschi N; Sbragia E; Laroni A; Capello E; Inglese M
    J Neurol Sci; 2021 Aug; 427():117501. PubMed ID: 34044238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Psychological status of patients with relapsing-remitting multiple sclerosis during coronavirus disease-2019 outbreak.
    Stojanov A; Malobabic M; Milosevic V; Stojanov J; Vojinovic S; Stanojevic G; Stevic M
    Mult Scler Relat Disord; 2020 Oct; 45():102407. PubMed ID: 32702641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The disease course of multiple sclerosis before and during COVID-19 pandemic: A retrospective five-year study.
    Babtain F; Bajafar A; Nazmi O; Badawi M; Basndwah A; Bushnag A; Cupler E; Hassan A
    Mult Scler Relat Disord; 2022 Sep; 65():103985. PubMed ID: 35759904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serious infections in patients with relapsing and progressive forms of multiple sclerosis: A German claims data study.
    Knapp R; Hardtstock F; Krieger J; Wilke T; Maywald U; Chognot C; Muros-Le Rouzic E; Craveiro L
    Mult Scler Relat Disord; 2022 Dec; 68():104245. PubMed ID: 36306609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. COVID-19 and its implications on the clinico-radiological course of multiple sclerosis: A case-control study.
    Rahmani M; Moghadasi AN; Shahi S; Eskandarieh S; Azizi H; Hasanzadeh A; Ahmadzade A; Dehnavi AZ; Farahani RH; Aminianfar M; Naeini AR
    Med Clin (Barc); 2023 Mar; 160(5):187-192. PubMed ID: 36089420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extending rituximab dosing intervals in patients with MS during the COVID-19 pandemic and beyond?
    Maarouf A; Rico A; Boutiere C; Perriguey M; Demortiere S; Pelletier J; Audoin B;
    Neurol Neuroimmunol Neuroinflamm; 2020 Sep; 7(5):. PubMed ID: 32587103
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Masked face recognition in patients with relapsing-remitting multiple sclerosis during the ongoing COVID-19 pandemic.
    Kuzu Kumcu M; Tezcan Aydemir S; Ölmez B; Durmaz Çelik N; Yücesan C
    Neurol Sci; 2022 Mar; 43(3):1549-1556. PubMed ID: 34988718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distinct intrathecal inflammatory signatures following relapse and anti-COVID-19 mRNA vaccination in multiple sclerosis.
    Bruno A; Buttari F; Dolcetti E; Azzolini F; Borrelli A; Lauritano G; Di Caprio V; Rizzo FR; Gilio L; Galifi G; Furlan R; Finardi A; Guadalupi L; Musella A; Mandolesi G; Centonze D; Stampanoni Bassi M
    Mult Scler; 2023 Oct; 29(11-12):1383-1392. PubMed ID: 37698019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A one year follow of patients with multiple sclerosis during COVID-19 pandemic: A cross-sectional study in Qom province, Iran.
    Paybast S; Hejazi SA; Molavi P; Habibi MA; Naser Moghadasi A
    Mult Scler Relat Disord; 2022 Apr; 60():103712. PubMed ID: 35247752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of delaying ocrelizumab dosing in multiple sclerosis due to COVID-19 pandemics on clinical and laboratory effectiveness.
    Barun B; Gabelić T; Adamec I; Babić A; Lalić H; Batinić D; Krbot Skorić M; Habek M
    Mult Scler Relat Disord; 2021 Feb; 48():102704. PubMed ID: 33370649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of Getting COVID-19 in People With Multiple Sclerosis: A Case-Control Study.
    Iaffaldano P; Lucisano G; Manni A; Paolicelli D; Patti F; Capobianco M; Brescia Morra V; Sola P; Pesci I; Lus G; De Luca G; Lugaresi A; Cavalla P; Montepietra S; Maniscalco GT; Granella F; Ragonese P; Vianello M; Brambilla L; Totaro R; Toscano S; Malucchi S; Petracca M; Moiola L; Ferraro D; Lepore V; Mosconi P; Ponzio M; Tedeschi G; Comi G; Battaglia MA; Filippi M; Amato MP; Trojano M;
    Neurol Neuroimmunol Neuroinflamm; 2022 Mar; 9(2):. PubMed ID: 35046084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SARS-CoV-2 infection and seroprevalence in patients with multiple sclerosis.
    Piñar Morales R; Ramírez Rivas MA; Barrero Hernández FJ
    Neurologia (Engl Ed); 2021; 36(9):698-703. PubMed ID: 34103271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.